Select Page

FSR Updates

Stay up-to-date on FSR’s latest activities and learn about the ways that FSR is driving progress and accelerating research towards a cure.

FSR launched the Ignore No More: ACTe Now! Campaign (Advance Clinical Trials for Equity in Sarcoidosis) to address the underrepresentation of Black Americans in clinical trials. As part of the campaign, FSR conducted the first of its kind, IRB-approved national patient survey for Black Americans to better understand the challenges and experiences Black Americans with sarcoidosis face as it pertains to clinical trials and their disease journeys. FSR also conducted a Key Opinion Leaders Thought Workshop (KOL) and Patient Focus Group to explore the findings in greater depth and to identify recommendations for how to improve clinical trial access and overall care of Black sarcoidosis patients.

Some recommendations that emerged include building a blueprint for clinical trial design that increases access and supports diversity, clinical trial navigation and support specifically targeted for Black patients, and educational toolkits to better educate patients and physicians about trial opportunities and engagement. Though this campaign was specific to Black Americans with sarcoidosis the learnings are relevant to improving access to clinical trials for all Black Americans.

Toolkits

White Papers

Annual Updates

Press Releases

FSR Blog

Ignore No More: Foundation for Sarcoidosis Research Launches African American Women & Sarcoidosis Campaign

October 12, 2021

The Foundation for Sarcoidosis Research (FSR) is excited to announce the official launch of the first of its kind African American Women & SarcoidosisLearn More

How to have a good doctor’s visit

October 12, 2021

How to have an effective office visit with your provider:   Getting the most of your office visits can be tricky, especially if you’reLearn More

Mary’s Anniversary

October 1, 2021

Mary McGowan’s Reflections on her First Year Anniversary as FSR’s CEO   Over the last year, I learned how resilient the FSR community is,Learn More

WHO Air Quality Guidelines Update: Health experts urge nations to implement ambitious air pollution reduction policies

September 24, 2021

Health experts urge nations to implement ambitious air pollution reduction policies Health experts and patient representative groups have issued a joint statement urging nations toLearn More

aTyr Pharma Announces Positive Data from Phase 1b/2a Pulmonary Sarcoidosis Clinical Trial

September 24, 2021

On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to haveLearn More

Living with ILD: A Sarcoidosis Patient Perspective

September 15, 2021

My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did theLearn More

older male doctor speaking to younger female doctor

Update on Coronavirus, COVID-19

August 30, 2021

COVID-19 Vaccine Boosters for Immunocompromised Patients

August 23, 2021

Sarcoidosis does not automatically indicate an immunocompromised diagnosis. FSR cannot determine or provide recommendations for your individual immunocompromised status. Please consult your physician forLearn More

Introducing the FSR Patient Speakers’ Bureau

July 19, 2021

We are thrilled to announce the formation of our new FSR Patient Speakers’ Bureau!   This bureau consists of 14 experienced and trained sarcoidosisLearn More

FSR-MNK Sarcoidosis Research Fellow Awarded for 2021-2023

June 4, 2021

The Foundation for Sarcoidosis Research (FSR) is pleased to announce the Foundation for Sarcoidosis Research Fellowship Grant for 2021-2023 is being awarded to Dr.Learn More

Translate »